(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) ...

Sci­ence 37, one of the star­tups that fu­eled the rise in de­cen­tral­ized clin­i­cal tri­als, will go pri­vate and see its one-time $1 bil­lion val­u­a­tion evap­o­rate … ...

Pfiz­er’s lat­est two-at-once vac­ci­na­tion mes­sag­ing taps in­to a hol­i­day theme. A TV com­mer­cial and Tik­Tok ad both cel­e­brate “pie sea­son” with the mes­sage that even … ...

HHS on Fri­day an­nounced its se­lec­tions for the next-gen­er­a­tion of Covid-19 vac­cine can­di­dates to re­ceive $500 mil­lion in fund­ing as part of the gov­ern­ment’s Project … ...

The Fed­er­al Trade Com­mis­sion wants more in­for­ma­tion on Pfiz­er’s takeover of Seagen be­fore it will make a rul­ing on whether it will clear the … ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

No­va­cyt made a cash of­fer for mol­e­c­u­lar di­ag­nos­tics and screen­ing so­lu­tions com­pa­ny Your­gene Health as it ad­justs from a ma­jor drop in rev­enue due to … ...

→ There’s a shake­up at the top of Chemomab Ther­a­peu­tics as the Is­raeli biotech halts the start of a Phase II study to save cash … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...

On Wednes­day, Rel­ma­da Ther­a­peu­tics ran in­to yet an­oth­er ma­jor prob­lem for its lead can­di­date, two months af­ter fac­ing an ear­li­er set­back.